Are you Dr. Mega?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 62 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-723-8392
Summary
- Dr. Jessica Mega, MD is a cardiologist in Stanford, California. She is currently licensed to practice medicine in California and Massachusetts. She is affiliated with Stanford Health Care and is an Assistant Professor at Harvard Medical School.
Education & Training
- Massachusetts General HospitalFellowship, Cardiovascular Disease, 2004 - 2008
- Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
- Yale School of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2016 - 2026
- MA State Medical License 2004 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 1337 citationsRivaroxaban in Patients with a Recent Acute Coronary SyndromeJessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Jean-Pierre Bassand, Deepak L. Bhatt
The New England Journal of Medicine. 2012-01-04 - 1790 citationsCytochrome P-450 Polymorphisms and Response to ClopidogrelJessica L. Mega, Sandra L Close, Stephen D. Wiviott, Lei Shen, Richard D. Hockett
The New England Journal of Medicine. 2009-12-10 - 710 citationsClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateStuart A. Scott, Katrin Sangkuhl, Charles M. Stein, Jean-Sébastien Hulot, Jessica L. Mega
Clinical Pharmacology and Therapeutics. 2013-09-01
Press Mentions
- Google’s Low-Tech Plan to Solve the Opioid CrisisSeptember 27th, 2022
- Regulatory Roundup: FDA Clears AI-Powered Apple Watch Competitor, Grants Breakthrough Designation to New Heart Failure DeviceJuly 25th, 2022
- The Top 5 Predictions About the Future of Health from Leaders in the SpaceMay 13th, 2022
- Join now to see all
Grant Support
- Genetic Determinants Of The Response To Thienopyridine TherapyNational Heart, Lung, And Blood Institute2010–2011
Professional Memberships
- Member